Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial)
Methods Data were obtained from trials with subcutaneous and intravenous administration of semaglutide that utilised frequent PK sampling and included a total of 353 subjects with 10,573 concentration values
When appropriately tailored to the individual, these diets may complement semaglutide therapy by supporting treatment adherence, enhancing metabolic outcomes, and potentially mitigating GI AEs
By addressing the root causes of overeating and helping to manage appetite, Wegovy ensures that weight loss is not just a short-term achievement but a sustainable lifestyle change
Semaglutide is a medication that mimics the effect of GLP-1, a hormone produced in your gut after you eat, and it has several effects on your body, such as: Stimulating insulin secretion and lowering blood sugar levels Slowing down gastric emptying and reducing food intake Increasing energy expenditure and fat-burning Reducing appetite and hunger Enhancing satiety and fullness Semaglutide was originally approved by the FDA as a treatment for type 2 diabetes, and in 2021, it was approved for chronic weight management in adults
